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1. Introduction 
Cardiovascular diseases and venous thromboembolism are multifactorial diseases. Risk 
factors result from genetics, environment and behavior. The concept of the multicausal 
disease has received much attention in recent years. One of the reasons is that some of the 
genetic risk factors concerning single point mutations are quite common in the general 
population. There are known molecular factors which increase the relative risk for disease, 
and others with protective effects. The genetic background is given by the combination of all 
these molecular markers.  
Several genetic variants are currently identified as risk factors for venous and arterial 
thrombosis (myocardial infarction and deep venous thrombosis)(Table 1). Activated protein 
C (APC) resistance due to the factor V Leiden mutation (FVL) and the 20210 G>A mutation 
in the factor II (FII, Prothrombin) gene are well established causes of thrombophilia. 
Concerning the risk of myocardial infarction the results are different (Ozmen F et al., 2009).  
The 677C>T mutation in the methylentetrahydrofolate reductase gene (MTHFR 677C>T), 
which causes a mild hyperhomocysteinemia, is considered to be a risk factor for coronary 
heart disease (Kluijtmans et al., 1997; Morita et al., 1997), venous thromboembolism and 
stroke (Frosst et al., 1995; Arruda et al., 1997; Margaglione et al., 1998, Khandanpour et al., 
2009, Tug E et al., 2011), but the results are controversial. 
New polymorphic markers of the FV gene were described in the last years (Lunghi et al., 
1996; Bernardi et al.,1997; Castoldi et al., 1997; Castoldi, 2000). A specific factor V gene 
haplotype (HR2) was defined by five restriction polymorphisms in exon 13 and a sequence 
variation located in exon 16. The exon 13 markers include the Rsa I polymorphic site, the 
rare allele of which (R2) has been previously found to be associated with partial FV 
deficiency in the Italian population (Lunghi et al., 1996). The nucleotide change 4070 G>A 
underlying the R2 allele gives rise to an amino acid change His to Arg at position 1299. 
Bernardi et al. (1997) demonstrated that the FV gene marked by the HR2 haplotype, which 
was invariably found to underlie the R2 marker, is both able to contribute to a mild APC 
resistance phenotype and to interact synergistically with the FVL mutation Arg506Gln to 
produce a severe APC resistance phenotype. Carriers of the R2 allele are more frequent 
among patients of carotid endarterectomy (Marchetti et al., 1999) and the carriership of the 
R2 allele is associated with an increased risk for coronary artery disease (Hoekema et al., 
1999; Hoekema et al., 2001) and venous thromboembolism (Bernardi et al., 1997; Faioni et al., 
1999; Alhenc-Gelas et al., 1999).  
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For some new variants of clotting factors FVII, FXII and FXIII associations with venous and 
arterial thrombosis were reported. Within the FVII gene eight polymorphisms are known 
(Herrmann et al., 1998; Herrmann et al., 2000) and three of them influence the level of FVII 
activity: the insertion polymorphism of the promotor (Marchetti et al., 1993), a tandem 
repeat unit polymorphism within intron 7 (Marchetti et al., 1991; de Knijff et al., 1994; 
Mariani et al., 1994; Pinotti et al., 2000) and the Arg353Gln polymorphism of exon 8 (Green 
et al., 1991). Iacoviello et al. (1998) demonstrated in patients with myocardial infarction and 
family history of cardiovascular diseases, that the Gln353 allele of the Arg353Gln 
polymorphism and the 7(a) allele of the tandem repeat unit polymorphism of the 
hypervariable region 4 within intron 7 might have a protective effect on the risk of 
myocardial infarction. These alleles independently showed an effect in reducing the risk and 
both were associated with lower levels of FVII (Green et al., 1991; Mariani et al., 1994; 
Iacoviello et al., 1998; Domenico et al., 2000). 
For severe factor XII deficiency, an increased predisposition to venous thromboembolic 
diseases and myocardial infarction has been reported. Some cohort studies have shown a 
high prevalence of slightly reduced FXII levels in patients of deep venous thrombosis or 
coronary heart diseases (Mannhalter et al., 1987; Halbmayer et al., 1994; Franco et al., 1999; 
Zito et al., 2000), but more association studies in this field are necessary. The C>T mutation 
at nucleotide 46 in the 5´untranslated region of FXII (FXII 46C>T) is associated with a 
diminished plasma FXII level (Kanaji et al., 1998; Kohler et al., 1999; Zito et al., 2000) and the 
role of this polymorphism as a thrombophilic risk factor is under discussion. 
The G>T transition in exon 2 of the FXIII A subunit gene was reported to provide a 
protective effect against myocardial infarction (Kohler et al., 1998; Franco et al., 2000) and 
venous thrombosis (Catto et al., 1999; Franco et al., 1999; Rosendaal et al., 1999; Alhenc-
Gelas et al., 2000; Franco et al., 2001), but also an increased predisposition to primary 
intracerebral hemorrhage (Catto et al., 1998; Reiner et al., 2001).  
Many epidemiological studies have been performed to associate the presence (insertion, I) 
or absence (deletion, D) of a 287bp Alu repeat element in intron 16 of the ACE (Angiotensin 
Converting Enzyme) gene with the level of the circulating enzyme or cardiovascular 
pathophysiology. Some reports have found that the D allele confers increased susceptibility 
to cardiovascular diseases and myocardial infarction, others found no such association or 
even a beneficial effect (Rieder et al., 1999; Agerholm-Larsen et al., 2000). The same is true 
for cerebrovascular diseases, stroke or stenosis of carotids and venous thrombosis (Philipp 
et al., 1998; Della Valle et al., 2001). Markus et al. (1995) reported that the DD genotype is a 
risk factor for lacunar stroke but not for carotid atheroma. However, the precise role of the 
I/D polymorphism is not clear, so more association studies are necessary. 
A series of studies have been carried out to elucidate the mechanisms of the athero-
thrombotic pathology in the middle-age and older adults. However, few studies have 
examined the joint effect of interaction of environmental factors and molecular markers in 
the risk of thrombosis particularly among the young. However, these claims have been 
challenged. Based upon in this observation it was considered important to study the role of 
the risk factors and molecular markers for thrombosis in Hispanics living in Costa Rica, 
Central America. In the population of Costa Rica (CR) and its different ethnic groups the 
prevalence of molecular risk and protective factors are few reports until now. In order to 
estimate the role of these factors in this population it is necessary to know their prevalence 
and it will be interesting to compare with one Caucasian population as NE Germany, see 
Figure 1. 
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Fig. 1. The approximate geographic locations of the six tribes of CR Amerindians 
2. A brief history of Costa Rican population 
The current population of Costa Rica presents an ancestral gene combination of 
Amerindians (30%), Africans (10-15%) and Caucasians (50-60%) (Barrantes, 1998). In the pre-
Columbian period, the human population in this area was composed of Amerindian tribes 
descending from the Na-dene and North-American Eskimos (Torroni et al., 1994). Four of 
the tribes studied (Guatuso, Guaymi, Cabecar, Bribri) belong to Chibcha-speaking tribes of 
lower Central America (Thompson et al., 1992; Barrantes, 1998). The Chibcha, which have 
been separated biologically and linguistically from other groups of this region, show 
differences in some aspects when compared to other North and South American groups of 
Indians (Barrantes et al., 1990; Thompson et al., 1992) and also have rare genetic variants 
and private polymorphisms.  
The Chorotega, another tribe included in the present study (Figure 1), belong to the 
Mesoamerican culture with strong influences from the Aztec and Maya culture (Ibarra, 
2001). At present, this tribe is located in the western Pacific area of the country. 
The Huetar tribe inhabited the North-Central area of Costa Rica during the time of the 
Spanish Conquest. At the present time, they are located in the southwest of the country 
(Figure 1). During colonization, the admixture between Spanish colonizers, mostly from the 
south of Spain, and indigenous women began (Thiel, 1977; Ibarra, 2001).  
In the 16th and 17th centuries Africans were firstly brought to Costa Rica by the transatlantic 
slave trade from western and Central Africa. The first settlement of Africans in Costa Rica 
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was in the Pacific area (Meléndez and Duncan, 1989). From the beginning, this ethnic group 
participated in the admixture process with the Amerindians. The second important African 
migration to Costa Rica was into the Caribbean Area during the 18th and 20th centuries. This 
group of Africans migrated from the Antilles, principally from Jamaica, and settled in 
"Cahuita" in the Limon province at the Atlantic coast (Palmer, 2000).  
Genotype prevalence and allele frequencies of the eleven molecular markers in Costa 
Rica Indians from six different tribes and Cr-Africans as well as blood donors from Costa 
Rica and NE Germany  
The results of the prevalence of these molecular markers in this ethnic context are 
summarized in Table 1, 2, 3 and 4. 
2.1 FII 20210G>A 
The 20210A allele of the factor II polymorphism was extremely rare in CR-Indians (Table 2). 
Only one allele was detected in the Bribri and one in the Huetar Indians. In CR-Africans, the 
20210A allele frequency was also extremely low (1 out of 578 alleles). In a cooperative study 
including more than 5500 healthy subjects from nine European and American countries, the 
overall prevalence of heterozygous FII carriers was estimated to be 2% (Rosendaal et al., 
1998). In the same study a very low prevalence of the prothrombin mutation was reported 
for Africans and subjects of Asian descent (Rosendaal et al., 1998). Therefore, we conclude 
that the FII mutation found in CR-Indians and CR-Africans is of Caucasian origin, as 
suggested for FVL.  
2.2 FV gene : FVL, FVHR2, FV IVS16 
The factor V Leiden mutation is a known risk factor for venous thrombosis in Caucasians 
and has been discussed as a risk factor for arterial thrombosis. This mutation was rare in 
CR-Indians, with only five heterozygous FVL carriers detected among the Huetar. In the 
CR-Indian tribes without FVL, the frequency of the R2 allele of the HR2 haplotype was 
extremely high. It has been shown that this allele is associated with partial FV deficiency 
and acts synergistically with FVL (Bernardi et al., 1997; Lunghi et al., 1998). In various 
populations the R2 allele frequency ranged from 0.04 to 0.08; Netherlands 0.040 (De Visser 
et al., 2000); England 0.055 (Luddington et al., 2000); Italy, India, Somalia 0.080 (Bernardi et 
al., 1997; Faioni et al., 1999; ); Germany 0.070 (Hermann et al., 2001 and this study). The 
extremely high frequency of the R2 allele and the R1R2 and R2R2 genotypes in Bribri 
Indians is the highest reported so far. In the same CR Indian tribes with a high prevalence of 
the R2 allele, the D2 allele of FV IVS16 polymorphism was very rare. 
The FVL mutation was likewise rare in the other CR groups analyzed (subpopulations of 
CR-Africans and in the CR blood donors). The R2 frequency of the HR2 haplotype was 
lower in the CR-Africans than in CR-Indians and CR-blood donors. However, in CR-
Africans the rare R3 allele (His1254Arg) was also detected. This allele was first described in 
subjects from Somalia and in Greek Cypriotes and mimics the R2 polymorphism 
(His1299Arg) in subjects of African origin (Lunghi et al., 1998). The FVL mutation was not 
found in combination with the R2 or R3 allele in CR-Africans or CR-blood donors . 
In the German group of 170 blood donors, 11 heterozygous FVL genotypes were detected. 
Eight of them had the R1R1 genotype and only three FVL heterozygotes had the R1R2 
genotype. All the eleven FVL heterozygous subjects were also heterozygous for the D2 
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* Unknown effect.  
Table 1. Characteristics of the different polymorphisms analyzed  
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*Allele frequency 
Table 2 Prevalence of polymorphisms in the FII and FV genes in the different ethnic groups 
studied 
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*Allele frequency 
Table 3. Prevalence of polymorphisms in the FVII gene in the different ethnic groups 
studied 
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*Allele frequency 
Table 4. Prevalence of polymorphism in the FXII, FXIII, ACE and MTHFR genes in the 
different ethnic groups studied 
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allele. On the other hand, only 45.80% of the D1D2 heterozygous subjects also had the 
heterozygous FVL genotype (Herrmann et al., unpublished).  
The similar high frequency of the FV D2 allele in CR-Africans and in German Caucasians 
supports the hypothesis that this is a very old ancestral mutant allele (Bernardi et al., 1997; 
Castoldi et al., 1997), dating back to a time prior to the human migration out of Africa. The 
absence of FVL in native populations of Africa, eastern Asia, Australasia and in CR Indians 
is well known (Rees et al., 1995; Herrmann et al., 1997; Herrmann et al., 1999 and this study). 
The different distribution of the FVL and of the FVHR2 haplotypes supports the hypothesis 
that the HR2 haplotype is also older than FVL and represents an ancient set of mutations 
(Bernardi et al., 1997; Faioni, 2000). Both the R2 and the D2 mutations seem to have 
originated in a single mutation event in different ancestral wildtype alleles of the FV gene. 
The high frequency of the R2 allele in CR-Indians without FVL as well as the extremely low 
frequency of the D2 allele in the same Indian tribes (< 0.50%) seems to indicate that the R2 
His1254Arg polymorphism is older than the FV IVS 16 polymorphism. 
The „out of Africa“ model of the origin of Homo sapiens sapiens provides a plausible 
explanation for the observed differences in the distribution of the three polymorphisms of 
FV gene among the different ethnic groups studied. This model suggests that non-African 
human populations were descended from an anatomically modern H. sapiens ancestor that 
evolved in Africa approximately 100,000 to 200,000 years ago and then spread and 
diversified throughout the rest of the world (Tishkoff et al., 1996; Zivellin et al., 1997). The 
ancestral population of Africans is characterized by the FV haplotypes of HR2 with the 
mutant alleles R2 and R3 and the FV-IVS16 polymorphism. We found these haplotypes in 
CR-Africans, who reached the Costa Rican area in the post-Columbian time, coming from 
the sub-Saharan African population (Ibarra, 2001). The similarity in the frequency of D2 and 
R2 in Africans and in Caucasoid subpopulations outside of Africa, including Europeans, 
Jews, Israeli Arabs and from India (Zivellin et al., 1997; Herrmann et al., 2001) is consistent 
with the migration of modern humans out of northeast Africa into the Middle East and 
Europe and out of southeast Africa to Asia, the Pacific Islands and the New World. Studies 
of both mitochondrial and nuclear DNA have suggested that the ancestral population 
leaving Africa towards the Southeast around 60,000 years ago was small (Tishkoff et al., 
1996). The migration to Asia and the New World was accompanied by a further reduction of 
the rare D2 allele, probably by random genetic drift. This assumption provides a possible 
explanation for the absence or extremely low frequency of the D2 allele in the CR-Indians. 
Further studies of other populations descended from the Southeast migrators are needed in 
order to confirm this speculation. 
Schröder et al. (2001) demostrated in German patients with deep venous thrombosis that 
FVL in Caucasians was always combined with the D2 allele. The investigation of 25 
homozygous FVL thrombotic patients from Germany also showed homozygosity for D2D2, 
indicating that both mutations (FVL and D2) are localized as double mutations in the same 
allele (Herrmann et al., unpublished data). These results support a single origin hypothesis 
(Castoldi et al., 1997; Zivellin et al., 1997), indicating that the FVL mutation in European 
Caucasians has its ancestral origin in a D2 marked allele of the FV gene of a modern 
Caucasoid subpopulation, now widespread among the Indo-European group. 
The FVL mutation is estimated to have arisen ca. 21,000 to 34,000 years ago, i.e. after the 
evolutionary divergence of Africans from non-Africans and of the Caucasoid from the 
Mongoloid subpopulation (Zivellin et al., 1997). The three FVL mutation carriers found in 
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CR-Africans are compound-heterozygous for FVL and D2 (D1D2, FVL/FVwt), and probably 
have a European/Caucasian origin caused through racial admixture in the past.  
2.3 FVII gene: FVII IVS7, FVII R353Q and FVII IVS1a polymorphism 
Epidemiological studies have shown that high blood levels of FVII are associated with an 
increased risk of ischaemic heart disease (Meade et al., 1986; Heinrich et al., 1994; Benardi et 
al., 1997). Environmental and biochemical factors influence the plasma level of FVII. Age, 
gender, BMI, insulin resistance and the use of oral contraceptives have been associated with 
FVII levels (Balleisen et al.,1985). Dietary fats and blood lipids are important determinants of 
FVII levels (Miller et al.,1991; Mennen et al.,1996). Several studies have demonstrated that 
three polymorphisms of the FVII gene can directly influence the FVII levels and also 
modulate its response to environmental stimuli (Lane et al., 1992; Humphries et al., 1994; 
Hong et al., 1999) 
The Gln353 variant of the FVII gene has consistently been associated with lower levels of 
FVII in white Europeans (Humphries et al., 1994), Gujarati Indians (Lane et al., 1992), 
Afrocaribbean Britains (Lane et al., 1992; Temple et al., 1997) and Japanese (Kario et al., 
1995). Individuals with the GlnGln genotype have a decreased risk for MI, and they have a 
lower level of FVII activity and FVII antigen in comparison to the ArgGln and homozygous 
Arg genotypes (Iacovello et al., 1998).  
The Gln allele frequencies of the Arg353Gln polymorphism in NE Germany, CR-blood 
donors and CR-Africans were similar to those described in other studies ( Bernardi et al., 
1997; Di Castelnuovo et al., 1998). The Gln allele frequencies of the Arg353Gln 
polymorphism in NE Germany and various ethnic groups in Costa Rica ranged from 0.010 
to 0.153 (Table 3). Significant differences in the allele frequencies in the Costa Rican groups 
were found. Among 627 CR-Indians, the homozygous GlnGln form was not found. The 
frequency of the mutant allele was lower in the CR-Indian groups (0.060) than in the North 
European populations (0.100) (Lane et al., 1992; de Maat et al., 1997). Smoking is a known 
risk for MI, but Iacoviello et al. (1999) and Niccoli et al. (2001) showed a decreased in the risk 
of MI in smokers subjects carrying the Gln353 allele.  
Concerning the FVII IVS7 polymorphism, it is known that the 5 monomers genotypes are 
associated with the highest risk for MI, followed in descending order by the 66, 67 and 77 
genotypes (Iacoviello et al., 1998; Niccoli et al., 2001). The frequency of the 7 allele was 
similar in German and CR-African population and slightly lower in CR-blood donors and 
CR-Indians. The prevalence of the 77 genotype was higher in the Chorotega (24.00%) and 
Bribri (17.82%) Indian groups, followed by CR-Africans (16.15%), in comparison with CR-
blood donors (7.86%). In Chorotegas Indians, the potentially higher risk caused by the 
absence of the protective homozygous Gln353 genotype seems to be compensated by the 
high prevalence of the 77 genotype. The 5 monomers with a high risk for MI were only 
found in CR-groups. Moreover, the 4, 8 and 9 monomers were detected for first time in CR-
ethnic groups. 
The influence on FVII activity of the recently described polymorphism within the promotor 
region of the FVII, the G>A transition at nucleotide 73 in the intron 1a, is not yet known 
(Herrmann et al., 2000). In this study, we report the lowest frequency of the rare mutant 
allele in the CR- Indian group (0.058) and the highest in the CR-Africans (0.222). In the NE-
Germans and the CR-blood donors, the frequency of the rare mutant allele was not 
significantly different.  
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2.4 FXII 46C>T  
There are several reports of severe FXII deficiency in subjects with thrombotic events or MI, 
cohort as well as case control studies have reported an increased predisposition to vascular 
thrombosis, ( Mannhalter et al., 1987; Halbmayer et al., 1994; Pandita et al., 1997). Other 
authors did not find a decrease of FXII to be a determinant of thrombosis (Lämmle et al., 
1991; ; Koster et al., 1994) or CVD (Kelleher et al.,1992; Kohler et al., 1999). 
The FXII 46 C>T mutation was found to be associated with diminished plasma FXII levels in 
homozygous and heterozygous carriers in comparison with normal individuals, principally 
in the homozygous form. These low plasma FXII levels were caused by the decreased 
translation efficiency of the mutant messenger RNA (Kanaji et al., 1998). The FXII 46C>T 
mutation exhibits an ethnic variability that might contribute to the racial differences 
observed in FXII plasma levels. In Orientals, the FXII level is lower than in Caucasians 
(Kanaji et al., 1998). The allele frequency of 46C/T was estimated to be 0.270/0.730 in 
Orientals and 0.800/0.200 in Caucasians. Franco et al. (1999) reported an allele 46T 
frequency of 0.250 in Whites and 0.320 in Blacks (n 19) and Mulattos (n15).  
In the present study, the 46T allele frequency in NE Germany (0.186) was in the range of 
other Caucasians reports (Kanaji et al., 1998, (0.200); Kohler et al., 1999, (0.280). In Costa 
Rica the frequency of the FXII 46T allele in CR- blood donors (0.300) was significantly higher 
than in the German population. The highest frequency was observed in the CR-African 
group (0.486) and more than 30 % of the CR-Africans from Limon were homozygotes for the 
T allele (Table 4). This is the highest rate reported in any population to date.  
Among 1182 alleles, 734 T alleles were detected in the CR-Indians (allele frequency 0.620), 
but the frequency differed between the various tribes. the prevalence of the homozygous 
wild type and heterozygous genotypes was higher than expected. In the 591 CR-Indians, the 
prevalence of the TT genotype was significantly higher (15.23%) than in Germans (6.19%).  
The role of this mutation as a risk factor in these populations is unclear and further studies 
are necessary. Franco et al. (1999) discussed that this mutation alone is probably not a major 
risk factor for venous thrombotic disease. Zeerleder et al. (1999) have shown that hereditary 
partial and probably severe FXII deficiency does not constitute a thrombophilic condition. 
The possibility of interactive effects of the FXII mutation with other genetic effects 
associated with vascular thrombosis and coronary artery disease need to be investigated. 
2.5 FXIII Val34Leu  
The FXIII Val34Leu was shown to confer protection for arterial and venous thrombosis and 
to predispose to intracerebreal hemorrhage (Kohler et al., 1998; Catto et al., 1998; Catto et al., 
1999; Franco et al., 1999; Rosendaal et al., 1999). These findings support the hypothesis that 
the factor XIII Leu34 is involved in the production of weaker fibrin structures which might 
protect against clot formation (Kohler at al., 1998; Catto et al., 1999). The mechanism 
underlying this protective effect is still unclear. The FXIII Leu34 variant gives rise to 
increased FXIII specific transglutaminase activity. Anwar et al. (1999) and Rosendaal et al. 
(1999) reported activities for FXIII ValVal of 96%, FXIII ValLeu:131% and FXIII LeuLeu: 
152% . 
The factor XIII Val34Leu polymorphism was originally described in a Finnish population 
with a Leu34 allele frequency of 0.230 in 600 normal controls (Mikkola et al.,1994). A 
frequency from 0.245 to 0.288 was reported for other Caucasian populations from three 
continents ( Balogh et al., 1999; Muszbek, 2000). In healthy South Asians, the Leu34 allele 
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frequency was less frequent (0.130) than in Whites (0.289) (McCormack et al.,1998; Kain et 
al., 1999). The allele frequency was also low in Brazilian Blacks (0.140) and African Blacks 
from Cameroon (0.118) and Angola (0.188) (Attie Castro et al., 2000). In the Japanese 
population the lowest frequency has been described (0.013) (Attie Castro et al., 2000). 
In the CR-Indians with a Chibcha origin (Cabecar, Bribri, Guaymi and Guatuso), the Leu34 
allele frequency (0.280) was similar to South Amerindians from Brazil and Peru (0.293) 
(Attie Castro et al., 2000). In contrast, the frequency of the mutant allele was lower (0.040) in 
the Chorotegas with Mesoamerican origin.  
The mutant allele frequency in CR-Africans (0.244) was similar to Africans (0.243) from 
Zaire (Attie Castro et al., 2000).  
2.6 MTHFR 677C>T 
The 677C>T mutation in the MTHFR gene was very frequent in CR groups, particularly in 
the CR-Indians (Table 4). The mutant allele frequency of 0.822 and the prevalence of 70% 
homozygous subjects found in Guaymi Indians is the highest reported in the literature to 
date. For comparison, in Yupka Indians from western Venezuela an allele frequency of 0.45 
(homozygosity 15%) was determined (Salazar-Sánchez et al., 1999; Vizcaino et al., 2001). In 
five Brazilian Amazonian tribes of Indians, Franco et al. (1998) found an allele frequency of 
0.240 (homozygosity 7.8%). Arruda et al. (1998) described in Amazonian Tupy Indians a 
frequency of 0.114 (homozygosity 1.2%). It seems that intertribal heterogeneity exists, which 
might be caused by isolation of small subpopulations and a high degree of consanguinity, as 
well as by genetic drift (Zago et al., 1996). This might also be an explanation for the 
deviations from the Hardy-Weinberg equilibrium we found in Guaymi Indians and CR-
Africans from Limon. The extremely high prevalence of the homozygous mutant allele (TT) 
in CR-Indians is remarkable, particularly considering that homozygosity has been discussed 
as a risk factor for cardiovascular diseases (CVD) caused by mild homocysteinemia.  
The relationship between homocysteine, folate, vitamin B12 levels and the MTHFR 677C>T 
was studied in Indians from Western Venezuela by Vizcaino et al. (2001). An elevated 
homocysteine level was detected in the homozygous TT group which could be partially 
explained by the folate deficiency found in this group. The implication for an increased risk 
of thrombotic events in the Yupka Indians from Venezuela does not appear to be relevant 
since the life expectancy in this population is relatively short and a high incidence of 
coronary complicactions has not been described (Diez-Ewald et al., 1999; Salazar-Sanchez et 
al., 2006). Clinical studies are necessary to determine the influence of this genotype on the 
prevalence of CVD in different ethnic groups and the relation with different life styles, e.g. 
folate level or vitamin B12 intake.  
In CR-Africans from Limon, the TT genotype and T allele frequency were similar to that of 
Caucasians. The higher frequencies of the T allele in the Guanacaste CR-Africans can 
probably be explained by admixture with Indians in this area since the 16th/17 th century 
(Ibarra, 2001). 
2.7 ACE 
The frequency of the D allele of the ACE polymorphism and the prevalence of the DD 
genotype were lower in CR-Indians than in CR-blood donors, CR-Africans or Germans 
(Table 4). Foy et al. (1996) reported a similar low frequency of the D allele in Pima Indians. 
CR-Africans had the same frequencies of the ACE DD genotype or D allele as Caucasians. 
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This was also reported for individuals from Nigeria, Jamaica and the United States (Rotimi 
et al., 1996). However, it is still not clear and results are conflicting, whether there is an 
association between the I/D polymorphism of the ACE gene (Rotimi et al., 1996; Sagnella et 
al., 1999) and serum ACE activity in people of African descent (Bloem et al., 1996). All these 
results clearly suggest that ethnic origin should be carefully considered in association 
studies between ACE genotype and disease etiology.  
Comparing the Indian tribes of this study, it appears that the Huetar Indians are a distinct 
group of CR-Indians. In Huetar Indians, the frequency of the FVL and ACE D-alleles was 
significantly higher and the R2-allele frequency of FV HR2 haplotype was lower than in the 
other tribes. These results are probably due to a higher degree of admixture with Europeans 
in the past, compared to other CR-Indian tribes (Barrantes et al., 1998; Ibarra, 2001). 
Concerning the frequencies of FV IVS16 and MTHFR polymorphisms, Chorotega Indians 
were different from Guatuso, Guaymi, Cabecar and Bribri, indicating their different origins. 
The similarity of the prevalence of the ACE polymorphism in the Chorotega and Bribri 
Indians is remarkable, but more markers should be studied before conclusions can be 
drawn. Note that in Chorotega Indians and CR-Africans from Guanacaste, ACE genotypes 
were not distributed as expected by the Hardy-Weinberg; the same although not significant 
tendency also occurred in Bribri Indians. One reason might be a higher degree of admixture 
with Caucasians, especially in the Chorotega, compared to the others tribes investigated in 
this study 
In conclusion, the present study has shown that genetic polymporphisms may vary 
appreciably within and between racial groups. Clear differences in the prevalence of studied 
polymorphisms were found between the different subpopulations in Costa Rica. These 
results indicate the importance of considering more than one molecular risk factor for 
determination of the risk or predisposition for a given disease. It is necessary to analyze a 
panel of molecular factors to determine the genetic background of a subject or population in 
order to estimate the genetical predisposition to disease. It was demonstrated that the 
prevalence of some established risk factors was lower in CR Indians than in Caucasians (D 
allele of ACE) or absent (FVLeiden, FII 20210G>A polymorphisms). Concerning the FVII 
polymorphism the protective 77 genotype was frequent only in the Chorotegas Indians, but 
the protective homozygous Gln353 genotype was absent in all CR-Indian groups.  
Knowledge of the prevalence of the studied polymorphisms in the Costa Rican populations 
provides the basis for follow studies of thrombosis in latinamerican populations. 
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